Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
OPERATING MARGIN
0.00%
OPERATING MARGIN AVG TTM
0.00%
OPERATING MARGIN AVG 3Y
0.00%
OPERATING MARGIN AVG 5Y
0.00%
OPERATING MARGIN AVG 10Y
0.00%
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 851 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
ENDRA Life Sciences Inc.
Market Cap
$7.75M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.73M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.89M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.92M
Operating Margin
-640.68%
TTM Avg
-11238.04%
3Y Avg
-10035.50%
5Y Avg
-9710.10%
Market Cap
$7.92M
Operating Margin
0.00%
TTM Avg
-476.50%
3Y Avg
-901.45%
5Y Avg
-600.97%
Market Cap
$7.98M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$8.14M
Operating Margin
N/A
TTM Avg
-193400.24%
3Y Avg
-134850.20%
5Y Avg
-97032.76%
Market Cap
$7.31M
Operating Margin
-0.52%
TTM Avg
-80.25%
3Y Avg
-135.01%
5Y Avg
-301.00%
Market Cap
$7.25M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ENDRA Life Sciences Inc. (NDRA) | $7.75M | 0.00% | 0.00% | 0.00% | 0.00% |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.73M | 0.00% | 0.00% | 0.00% | 0.00% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.89M | 0.00% | 0.00% | 0.00% | 0.00% |
| Traws Pharma, Inc. (TRAW)vs › | $7.92M | -640.68% | -11238.04% | -10035.50% | -9710.10% |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.92M | 0.00% | -476.50% | -901.45% | -600.97% |
| GT Biopharma, Inc. (GTBP)vs › | $7.98M | 0.00% | 0.00% | 0.00% | 0.00% |
| HeartSciences Inc. (HSCS)vs › | $8.14M | N/A | -193400.24% | -134850.20% | -97032.76% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | -0.52% | -80.25% | -135.01% | -301.00% |
| Skye Bioscience, Inc. (SKYE)vs › | $7.25M | 0.00% | 0.00% | 0.00% | 0.00% |
| Longeveron Inc. (LGVN)vs › | $7.21M | -1942.20% | -1316.46% | -1768.86% | -1413.19% |
Gross Margin
0.0%
Operating Margin
0.0%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | -45960.77% |
| 2017-12-31 | -33526.58% |
| 2017-09-30 | -317.40% |
| 2017-06-30 | -1829.36% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | -61.46% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | -178.60% |
| 2015-09-30 | -167.13% |
| 2015-06-30 | -26.13% |
| 2015-03-31 | -50.20% |
